Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VELCADE Administered by · 1 trial · 1 indication
Disease response was measured according to European Group for Blood and Marrow Transplantation (EBMT) criteria with the addition of the response categories of nCR and VGPR. Complete response requires disappearance of monoclonal protein from the blood and urine and \<5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks. Partial Response requires ≥50% reduction in serum m-protein for at least 2 determinations at least 6 weeks apart and if present, reduction in 24-hour urinary light chain excretion by either ≥90% or to \<200 mg
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | VELCADE administered by subcutaneous injection |
| 2 | ACTIVE_COMPARATOR | VELCADE administered by intravenous infusion |
| Name | Type | Description |
|---|---|---|
| VELCADE Administered by subcutaneous injection | DRUG | Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle |
| VELCADE Administered by intravenous infusion | DRUG | Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle. |
Inclusion Criteria: 1. Male or female subjects 18 years or older 2. Diagnosis of multiple myeloma 3. Measurable, secretory multiple myeloma defined as serum monoclonal IgG of ≥10 g/L, serum monoclonal IgA or IgE ≥5 g/L, or serum monoclonal IgD ≥0.5g/L; or urine M-protein of ≥200 mg/24 hr 4. Relapse...
Top 20 of 25 competitors
VELCADE is a small molecule drug being studied for the treatment of Multiple Myeloma. It is currently in Phase 3 clinical development and is being developed by Takeda Pharmaceutical Company Limited. The drug is administered by subcutaneous and intravenous routes in clinical trials.
VELCADE is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is in Phase 3 clinical development for Multiple Myeloma, an oncology indication. Takeda is conducting clinical trials to evaluate the safety and efficacy of VELCADE in patients with previously treated Multiple Myeloma.
VELCADE is in Phase 3 clinical development. It is being studied for the treatment of Multiple Myeloma. The drug is investigational and has not been approved by regulatory authorities based on the available information. A Phase 3 clinical trial has been completed to evaluate its effects.
VELCADE has one completed Phase 3 clinical trial with the identifier NCT00722566. This study, titled "A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma," enrolled 222 participants in Belgium, France, and Germany. The trial was active-controlled and randomized, with a minimum age of 18 years.
VELCADE is a small molecule drug being studied for Multiple Myeloma. The specific molecular target of VELCADE has not been disclosed in the available information. The drug is being evaluated in clinical trials to determine its mechanism of action and therapeutic effects in patients with previously treated Multiple Myeloma.
VELCADE is the brand name for bortezomib, a proteasome inhibitor used in the treatment of Multiple Myeloma. The drug is being developed by Takeda Pharmaceutical Company Limited. In clinical trials, VELCADE has been studied for its efficacy and safety in patients with previously treated Multiple Myeloma.